Nasdaq
$2.73▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $148.6MShares out 54.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 9.17After-hours26.09.18 05:054Ownership#●●●
Upstream Bio, Inc.
Insider Gray Michael reported a change in beneficial ownership of securities for Upstream Bio, Inc. as of September 16, 2026. This filing formalizes the insider's transaction details in accordance with Form 4 requirements.…more
$2.73+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17After-hours26.09.18 05:054Ownership
Upstream Bio, Inc.
Insider Ambrose Allison of Upstream Bio, Inc. filed a Form 4 statement of changes in beneficial ownership of securities on September 16, 2026. This filing officially records the changes in the insider's equity holdings.…more
$2.73+0.00%vs prev closeView filingShare - 9.17After-hours26.09.18 05:054Ownership
Upstream Bio, Inc.
Insider Deykin Aaron of Upstream Bio, Inc. reported a change in beneficial ownership of securities as of September 16, 2026. This filing is a Form 4 submission detailing the insider's equity transaction.…more
$2.73+0.00%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.8Overnight26.09.08 16:55#●●●#●●●
Upstream Bio Presents Phase 2 Results for Asthma Drug Verekitug
Upstream Bio presented the safety and efficacy results of its Phase 2 VALIANT trial for Verekitug in adults with severe asthma at the ERS Congress. The presentation highlighted clinical data, though further details on commercialization timelines remain to be seen.…more
$2.73+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.8Overnight26.09.08 16:30
●●●●●●●● ●●●●● ●●●●●●
Upstream Bio reported that its severe asthma treatment candidate, verekitug, reduced asthma exacerbation rates by 56% in a Phase 2 trial. The company remains on track to initiate Phase 3 clinical trials in the first quarter of 2027.…more
$2.73+0.00%vs prev close - 9.1Pre-market26.09.01 20:06
●●●●●●●● ●●●●● ●●●●●●
Upstream Bio plans to conduct Phase 3 clinical trials for Verekitug involving approximately 1,500 patients with severe asthma and CRSwNP. The company is on track to initiate these trials in the first quarter of 2027.…more
$2.73+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report